Antifungal agents: Resistance and rational use

Antibiotic Policies: Theory and Practice

Volumn , Issue , 2005, Pages 311-330

  Odds, Frank C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053524931     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-22852-7_17     Document Type: Chapter

References (78)

1. Abi-Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., and Vartivarian, S., 1997, The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis., 24, 1122-1128.
2. Asmundsdottir, L. R., Erlendsdottir, H., and Gottfredsson, M., 2002, Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J. Clin. Microbiol., 40, 3489-3492.
3. Baran, J., Muckatira, B., and Khatib, R., 2001, Candidemia before and during the fluconazole era: Prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand. J. Infect. Dis., 33, 137-139.
4. Barchiesi, F., Maracci, M., Radi, B., Arzeni, D., Baldassarri, I., Giacometti, A. et al., 2002, Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretro-viral therapy. J. Antimicrob. Chemother., 50, 999-1002.
5. Bennett, J. E., Powers, J., Walsh, T., Viscoli, C., de Pauw, B., Dismukes, W. et al., 2003, Forum report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin. Infect. Dis., 36, S117-S122.
6. Blignaut, E., Messer, S., Hollis, R. J., and Pfaller, M. A., 2002, Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn. Microbiol. Infect. Dis., 44, 169-174.
7. Bohme, A., Ruhnke, M., Karthaus, M., Einsele, H., Guth, S., Heussel, G et al., 2001, Treatment of fungal infections in haematology and oncology. Guidelines of the Working Party on Infections in Haematology and Oncology (AGIHO) of the German Society for Haematology and Oncology (DGHO). Dtsch. Med. Wochenschr, 126, 1440-1447.
8. Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G, Reboli, A. C., Schwarer, A. P. et al., 2001, Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy-a randomized, controlled trial. Ann. Intern. Med., 135, 412-422.
9. Bow, E. J., Laverdiere, M., Lussier, N., Rotstein, C., Cheang, M. S., and Ioannou, S., 2002, Antifungal prophylaxis for severely neutropenic chemotherapy recipients-a metaanalysis of randomized-controlled clinical trials. Cancer, 94, 3230-3246.
10. Canuto, M. M., Rodero, F. G, Ducasse, V O. D., Aguado, I. H., Gonzalez, C. M., Sevillano, A. S. et al., 2000, Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis., 19, 593-601.
11. Chen, Y. C, Chang, S. C, Luh, K. T., and Hsieh, W. C, 2003, Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother., 52, 71-77.
12. Chryssanthou, E., Torssander, J., and Petrini, B., 1995, Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand. J. Infect. Dis., 27, 391-395.
13. Denning, D. W., 1998, Invasive aspergillosis. Clin. Infect. Dis., 26, 781-803.
14. Denning, D. W., Kibbler, C. C, and Barnes, R. A., 2003, British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect. Dis., 3, 230-240.
15. Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D A. et al., 1997, Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother, 41, 1364-1368.
16. Dupont, B., Brown, H. H. C, Westermann, K., Martins, M. D, Rex, J. H., Lortholary, O. et al., 2000, Mycoses in AIDS. Med. Mycol., 38, 259-267.
17. Dykewicz, C. A., 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 33, 139-144.
18. Eggimann, P., Francioli, P., Bille, J., Schneider, R, Wu, M. M., Chapuis, G. et al., 1999, Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med., 27, 1066-1072.
19. Girmenia, C, Luzi, G, Monaco, M., and Martino, P., 1998, Use of voriconazole in treatment of Scedosporium apiospermum infection-case report. J. Clin. Microbiol., 36, 1436-1438.
20. Groll, A. H. and Walsh, T. J., 2001, Uncommon opportunistic fungi: New nosocomial threats. Clin. Microbiol. Infect., 7, 8-24.
21. Herbrecht, R, Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R E., Oestmann, J. W. et al., 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med., 347', 408-415.
22. Hughes, W. T., Armstrong, D, Bodey, G P., Bow, E. J., Brown, A. E., Calandra, T. et al., 2002, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis., 34, 730-751.
23. Husain, S., Tollemar, J., Dominguez, E. A., Baumgarten, K., Humar, A., Paterson, D L. et al., 2003, Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study. Transplantation, 75, 2023-2029.
24. Ives, N. J., Gazzard, B. G, and Easterbrook, P. J., 2001, The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect., 42, 134-139.
25. Kaufman, D, Boyle, R., Hazen, K C, Patrie, J. T., Robinson, M., and Donowitz, L. G, 2001, Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med., 345, 1660-1666.
26. Keye, J. D and Magee, W. E., 1956, Fungal infections in a general hospital. Am. J. Clin. Pathol., 26, 1235-1253.
27. Kicklighter, S. D., Springer, S. C, Cox, T., Hulsey, T. C, and Turner, R B., 2001, Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics, 107, 293-298.
28. Kovacicova, G, Spanik, S., Kunova, A., Trupl, J., Sabo, A., Koren, P. et al., 2001, Prospective study of fungaemia in a single cancer institution over a 10-y period: Aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand. J. Infect. Dis., 33, 367-374.
29. Krcmery, V. and Barnes, A. J., 2002, Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J. Hosp. Infect., 50, 243-260.
30. Kunova, A., Trupl, J., Demitrovicova, A., Jesenska, Z., Grausova, S., Grey, E. et al., 1997, Eight-year surveillance of non-albicans Candida spp in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis. Microb. Drug Res. Mech. Epidemiol. Dis., 3, 283-287.
31. Lin, S. J., Schranz, J., and Teutsch, S. M., 2001, Aspergillosis case-fatality rate: Systematic review of the literature. Clin. Infect. Dis., 32, 358-366.
32. Manavathu, E. K., Cutright, J. L., Loebenberg, D., and Chandrasekar, P. H., 2000, A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob Chemother, 46, 229-234.
33. Marr, K. and Boeckh, M., 2001, Practice guidelines for fungal infections: A risk-guided approach. Clin. Infect. Dis., 32, 321.
34. Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., and Corey, L., 2002a, Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood, 100, 4358-4366.
35. Marr, K. A., Carter, R. A., Crippa, F., Wald, A., and Corey, L., 2002b, Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 34, 909-917.
36. Marrazzo, J., 2003, Vulvovaginal candidiasis-over the counter treatment doesn't seem to lead to resistance. BMJ, 326, 993-994.
37. Martins, M. D., Lozanochiu, M., and Rex, J. H., 1997, Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis., 25, 843-846.
38. Martins, M. D., Lozano-Chiu, M., and Rex, J. H., 1998, Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin. Infect. Dis., 27, 1291-1294.
39. McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D. et al., 2001, Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Am. J. Hum. Genet., 33, 641-647.
40. Michel-Nguyen, A., Favel, A., Azan, P., Regli, P., and Penaud, A., 2000, Dix-neuf années de données épidémiologiques en centre hospitalier universitaire: place de Candida (Torulopsis) glabrata; Sensibilité. J. Mycol. Med., 10, 78-86.
41. Milan, E. P., Burattini, M. N, Kallas, E. G, Fischmann, O., Costa, P. R D., and Colombo, A. L., 1998, Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn. Microbiol. Infect. Dis., 32, 211-216.
42. Moran, G. P., Sullivan, D. J., Henman, M. C, McCreary, C. E., Harrington, B. J., Shanley, D. B. et al., 1997, Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (hiv)-infected and non-hiv-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother., 41, 617-623.
43. Munoz, P., Marin, M., Tornero, P., Rabadan, P. M., Rodriguez-Creixems, M., and Bouza, E., 2000, Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis., 31, 1499-1501.
44. Nucci, M. and Colombo, A. L., 2002, Risk factors for breakthrough candidemia. Eur J. Clin. Microbiol. Infect. Dis., 21, 209-211.
45. Odds, F. C, Brown, A. J. P., and Gow, N. A. R., 2003, Antifungal agents: Mechanisms of action. Trends Microbiol, 11, 272-279.
46. Pelz, R. K., Hendrix, C. W., Swoboda, S. M., Diener-West, M., Merz, W. G., Hammond, J. et al., 2001, Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients, Ann. Surg., 233, 542-548.
47. Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., and Hollis, R. J., 2003a, Activities of fluconazole and voriconazole against 1, 586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS global antifungal susceptibility program, 2001. J. Clin. Microbiol., 41, 1440-1446.
48. Pfaller, M. A., Jones, R N, Doern, G. V, Fluit, A. C., Verhoef J., Sader, H. S. et al., 1999a, International surveillance of blood stream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis., 35, 19-25.
49. Pfaller, M. A., Jones, R. N, Doern, G V, Sader, H. S., Messer, S. A., Houston, A. et al., 2000, Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother, 44, 747-751.
50. Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., and Diekema, D J., 2003b, Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol., 41, 2176-2179.
51. Pfaller, M. A., Messer, S. A., Hollis, R J., Jones, R. N, Doern, G V, Brandt, M. E. et al., 1999b, Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis., 33, 217-222.
52. Poggeler, S., 2002, Genomic evidence for mating abilities in the asexual pathogen Aspergillus fumigatus. Curr Genet., 42, 153-160.
53. Price, M. F., Larocco, M. T, and Gentry, L. O., 1994, Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemother, 38, 1422-1424.
54. Quilitz, R E., Arnold A. D, Briones, G R., Dix, S. P., Ippoliti, C, Kennedy, L. D. et al., 2001, Practice guidelines for lipid-based amphotericin B in stem cell transplant recipi ents. Ann. Pharmacother, 35, 206-216.
55. Quindos, G, Carrillo-Munoz, A. J., Arevalo, M. P., Salgado, J., Alonso-Vargas, R., Rodrigo, J. M. et al., 2000, In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy, 46, 395-401.
56. Raffaele, B., Sacchi, P., and Filice, G, 2003, Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: Impact of highly active antiretroviral therapy. AIDS, 17, S83-S87.
57. Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozanochiu, M., Espinelingroff, A., and Anaissie, E. J., 1998, Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother, 42, 129-134.
58. Rex, J. H., Pappas, P. G, Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S. et al., 2003, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin. Infect. Dis., 36, 1221-1228.
59. Rex, J. H, Rinaldi, M. G, and Pfaller, M. A., 1995, Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother, 39, 1-8.
60. Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G, Pappas, P. G, Dismukes, W. E. et al., 2000, Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis., 30, 662-678.
61. Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G. et al., 2000, Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis., 30, 710-718.
62. Sandven, P., 2000, Epidemiology of candidemia. Rev. Iberoamer. Micol., 17, 73-81.
63. Sanglard, D. and Odds, F. C., 2002, Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect. Dis., 2, 73-85.
64. Sims, M. E., Yoo, Y., You, H., Salminen, C., and Walther, F. J., 1988, Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am. J. Perinatol., 5, 33-36.
65. Singh, N., Wagener, M. M., Marino, I. R, and Gayowski, T., 2002, Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices. Transplantation, 73, 63-67.
66. Soll, D. R., Lockhart, S. R., and Zhao, R, 2003, Relationship between switching and mating in Candida albicans. Eukaryot. Cell, 2, 390-397.
67. St Germain, G, Laverdiere, M., Pelletier, R., Bourgault, A. M., Libman, M., Lemieux, C. et al., 2001, Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol., 39, 949-953.
68. Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W. et al., 2000, Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis., 30, 696-709.
69. Tacconelli, E., Bertagnolio, S., Posteraro, B., Tumbarello, M., Boccia, S., Fadda, G et al., 2002, Azole susceptibility patterns and genetic relationship among oral Candida strains isolated in the era of highly active antiretroviral therapy. Jaids, 31, 38-44.
70. Torres, H. A., Rivero, G A., Lewis, R. E., Hachem, R, Raad II, and Kontoyiannis, D. P., 2003, Aspergillosis caused by non-fumigatus Aspergillus species: Risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis., 46, 25-28.
71. Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., and Gaynes, R. P., 2002, Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis., 35, 627-630.
72. Verweij, P. E., Dorsthorst, D. T. A. T, Rijs, A. J. M. M., De Vries-Hospers, H. G, and Meis, J. F G M., 2002, Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J. Clin. Microbiol., 40, 2648-2650.
73. Walker, P. P., Reynolds, M. T., Ashbee, H. R., Brown, C, and Evans, E. G V, 2000, Vaginal yeasts in the era of "over the counter" antifungals. Sex Trans. Infect., 76, 437-438.
74. Walsh, T. J., Lutsar, I., Driscoll, T, Dupont, B., Roden, M., Ghahramani, P. et al., 2002, Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J., 21, 240-248.
75. White, T. C, 1997, Increased mrna levels of erg16, cdr, and mdr1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother, 41, 1482-1487.
76. Winston, D. J. and Busuttil, R. W, 2002, Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation, 74, 688-695.
77. Wisplinghoff, H., Seifert, H., Wenzel, R P., and Edmond M. B., 2003, Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis., 36, 1103-1110.
78. Yamazaki, T, Kume, H., Murase, S., Yamashita, E., and Arisawa, M., 1999, Epidemiology of visceral mycoses: Analysis of data in Annual of the Pathological Autopsy Cases in Japan. J. Clin. Microbiol., 37, 1732-1738.